CME Course - The Evolving Role of Imaging in the Diagnosis and Treatment of Prostate Cancer

Saturday, March 11, 2017 7:00-4:30pm


Prostate Cancer is the most common solid organ malignancy diagnosed in men. Unlike other solid organ malignancies, the challenge in prostate cancer is to confidently identify men with moderate and high-grade cancers who would most benefit from aggressive therapy. Uniquely among solid organ cancers, imaging has not been a traditional part of the workup of prostate cancer, which has relied instead on transrectal US-guided template biopsy. 

Over the past few years, MR imaging has emerged as the best imaging modality to detect, grade and stage prostate cancer. This unique one-day course will provide a comprehensive overview of the utility of multiparametric MR imaging for comprehensive cancer care. 

We will discuss all relevant MR imaging parameters for prostate cancer (T2, perfusion, diffusion, and spectroscopy) and discuss new standardized MR reporting algorithms for prostate cancer. In conjunction with the Yale Departments of Urology, Pathology, Diagnostic Radiology, and Radiation Oncology, we will review application of MR Imaging in surgical planning for robotic prostatectomy, prostate biopsy planning, active surveillance, and radiation planning. We will also discuss state-of-the-art MR/ US fusion biopsy and direct MR-guided planning for biopsy and treatment. The course will also include an opportunity for participants to interact with industry partners. 

The primary goal of this conference is to provide urologists, radiologists, primary care physicians and interventional radiologists with a comprehensive review of advances in prostate imaging, biopsy, and focal minimally invasive ablative therapy of prostate cancer. The course is designed for practicing and academic urologists, radiologists, primary care physicians, and interventional radiologists who are interested in learning about and adopting MRI into the diagnosis and management of prostate cancer – this will specifically include targeted prostate biopsy and focal minimally invasive ablative therapy for managing prostate cancer. Selecting candidates for these novel treatment options will also be emphasized.

6.75 AMA PRA Category 1 Credits(TM)

Jane Ellen Hope Building
1st floor auditorium
315 Cedar Street, New Haven, CT

The conference will also be available via a realtime streaming webinar. For those unable to physically attend, you may still participate and earn CME credit via an online meeting room live webinar. You will be able to hear the speaker, see the slides and text questions in a chat window to still participate in any Q&A. After registering, please email Jodi Canapp to obtain the weblink, username and password.

Learning Objectives

At the conclusion of this course, participants should be better able to:

  • Provide a comprehensive overview of state-of-the-art multiparametric prostate magnetic resonance imaging. 
  • Describe the benefit of prostate MR imaging for active surveillance and biopsy planning. 
  • Understand how prostate MR imaging can improve focal therapy, prostatectomy, and radiation therapy planning. 
  • Discuss standardized reporting/PIRADS. Describe advances in prostatic mpMRI, including contrast enhancement, and diffusion weighted imaging as well as the optimal timing for performing mpMRI post-biopsy. 
  • Evaluate and differentiate between different approaches for using MRI to guide prostate biopsy. 
  • Discuss factors that enhance effectiveness of minimally invasive procedures and establish and utilize treatment strategies that decrease complications
  • Discuss the emerging role of urine and serum biomarkers to identify men at increased risk for harboring clinically significant prostate cancer

Target Audience

Radiologists, urologists, radiation oncologists, interventional radiologists, and family practitioners interested in understanding prostate MR imaging and its applications to active surveillance, biopsy planning and acquisition, and treatment planning including surgery, radiation, and focal therapies.

Registration Information

Registration is completed online. Click here to register now

Physicians - $125 

Nurses/PAs/Allied Health Professionals - $75 

Residents/Fellows/Students/Research Scientists – Complimentary

Yale Faculty – Complimentary

Need Analysis 

The optimal strategy for accurate risk stratification of prostate cancer remains controversial. Practicing clinicians need to understand the strengths and limitations of using MRI to diagnose and stage prostate cancer. In addition, imaging can help stratify and appropriately select those men who require treatment, whether whole prostate or more selective focal minimally invasive therapies. In the past couple of years, evidence has emerged supporting MRI guided targeted biopsy. 

Accordingly, it is important for clinicians to examine the different perspectives on data introduced in the literature regarding diagnosis. MRI is underutilized in the work-up of men with elevated PSA and prostate cancer. Owing to advances in multiparametric MRI (mpMRI) of the prostate, this imaging modality should be considered in the selection of candidates for biopsy and for focal therapy. While level-one evidence is not available, clinicians need to rely on the experience and consensus of those experts in the field who are investigating the role of mpMRI for localizing prostate cancer. 

New biomarkers to stratify which patients should have a prostate biopsy have recently emerged. Clinicians should be able to evaluate which of these should be used in concert with PSA and/or MRI to determine candidacy for biopsy. There is increasing interest in minimally invasive ablative therapies for prostate cancer, yet few urologists actually offer this option to men with prostate cancer. 

Clinicians (urologists and radiologists) must better understand the advantage of more powerful magnets as well as diffusion imaging and contrast enhancement. Random TRUS guided biopsy has been shown to both under-stage and over-diagnose prostate cancer. There is growing evidence that MRI guided biopsy using cognitive co-registration with US or in-bore biopsy increases specificity of prostate biopsy without decreasing sensitivity for detecting clinically significant disease. Clinicians need to know the relative benefits of these approaches for improving accuracy of prostate biopsy. New imaging techniques are being used to detect and guide treatment of advanced/metastatic prostate cancer

Accreditation/Designation Statement 

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of the The Yale School of Medicine.  The Yale School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Yale School of Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy 

It is the policy of Yale University School of Medicine, through its Center for Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs.  All faculty participating in this symposium are required to disclose to the program audience any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest.  The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

Cancellation policy 

All cancellations must be received via e-mail at least one week prior to the start of the conference to receive a refund. Any requests for refunds received after this date, or by telephone, will not be honored. Email Jodi Canapp for any cancellations or questions



7:00am Registration, Breakfast and Check-in 

8:00am Overview: Why Imaging-Where Have We Been – Peter G. Schulam, MD, PhD  Professor of Urology 

State of the Art in Prostate Cancer Diagnosis
8:15am Prostate MR Imaging T2/Diffusion/Perfusion Steffen Huber, MD  Assistant Professor of Radiology and Biomedical Imaging 

8:45am Prostate Pathology – Peter A. Humphrey, MD, PhD  Professor of Pathology and Angelique Levi, MD  Assistant Professor of Pathology

9:15am MRI-Guided Fusion Biopsy – Preston C. Sprenkle, MD  Assistant Professor of Urology 

9:45am Current Controversies in Prostate Cancer Screening – Michael S. Leapman, MD  Assistant Professor of Urology 

10:15am Break/Visit Technology Showroom

10:30am Biomarkers: Urine and Serum – Michael S. Leapman, MD  Assistant Professor of Urology  

Case Presentation I Localized Prostate Cancer
11:00am Case Presentation – Preston C. Sprenkle, MD  Assistant Professor of Urology 

MRI ReviewJeffrey C. Weinreb, MD  Professor of Radiology and Biomedical Imaging 

Biopsy: Walk through of Artemis Biopsy – Preston C. Sprenkle, MD  Assistant Professor of Urology 

Pathology Review – Peter A. Humphrey, MD, PhD  Professor of Pathology and Angelique Levi, MD  Assistant Professor of Pathology 

Treatment Options:

  • How Imaging Informs Surgery  – John W. Colberg, MD  Professor of Urology
  • Imaging in Active Surveillance, Genomic Assays – Preston C. Sprenkle, MD


    Assistant Professor of Urology 
  • Focal Therapy  – Preston C. Sprenkle, MD  Assistant Professor of Urology 
  • Radiation Therapy  – Sameer K. Nath, MD  Assistant Clinical Professor of Therapeutic Radiology
  • Targeted Treatments: Embolization, Injections of Agents  - Raj R. Ayyagari, MD  Assistant Professor of Radiology and Biomedical Imaging 

12:00pm Discussion

12:30pm – 1:30pm Lunch/Visit Technology Showroom 

1:30pm Keynote Speaker “High Risk Prostate Cancer: Contemporary Treatment Paradigms, Outcomes, and Future Directions” Daniel W. Lin, MD Professor and Chief, Urologic Oncology; Vice Chair of Research; Pritt Family Endowed Chair for Prostate Cancer Research; Director, IPCR; Department of Urology, University of  Washington

2:30pm Advances in Medical Therapy of Advanced Disease – Daniel P. Petrylak, MD  Professor of Medicine and of Urology

3:00pm Break/Visit Technology Showroom

Case Presentation II Advanced Prostate Cancer 
3:15pm Case Presentation – Patrick A. Kenney, MD  Assistant Professor of Urology  

MRI Review - Jeffrey C. Weinreb, MD  Professor of Radiology and Biomedical Imaging 

New NM/SPECT Imaging Techniques – Lawrence A. Saperstein, MD  Assistant Professor of Diagnostic Radiology 

Pathology Review – Peter A. Humphrey, MD, PhD  Professor of Pathology and Angelique Levi, MD  Assistant Professor of Pathology 

Treatment Options:

4:15pm Discussion

4:45pm Adjour


Email Jodi Canapp with any questions

Travel information


This conference will be held at the Jane Ellen Hope Building, 1st Floor Auditorium, 315 Cedar Street, New Haven, CT.

From I-95 North or South:

Leave I-95 at Exit 47 (Downtown New Haven/Rte 34). This puts you onto an exit expressway. Merge onto CT-34 W via Exit 1 toward Downtown New Haven. Follow the short expressway, and merge into the left lane after the traffic light.  Turn left onto College Street, travel 0.4 mile then left onto Howard Avenue. In 0.1 mile turn left onto Washington Avenue. Lot 96 will be on the left and lot 47 will be on the right.

From I-91 South:

Leave I-91 South at Exit 1 (Downtown New Haven/Rte 34). This exit puts you onto a short expressway. Follow the short expressway, and merge into the left lane after the traffic light.  Turn left onto College Street, travel 0.4 mile then left onto Howard Avenue. In 0.1 mile turn left onto Washington Avenue. Lot 96 will be on the left and lot 47 will be on the right.

Parking information

Email Jodi Canapp for any questions